Why Is Hoth Therapeutics Stock Flying Higher On Tuesday?

On Tuesday, Hoth Therapeutics, Inc. HOTH shared interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors in cancer patients.Data from the open-label portion of the CLEER-001 trial demonstrated:100% of patients achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark.66% of patients reported reduced pain and itching scores, fur ...